HealthWACH: New hope for IBD

HealthWACH: New hope for IBD


Inflammatory bowel disease (IBD) is a chronic intemperate of all of the organs in your digestive tract. This usually includes Crohn's disease and uncreative colitis, and is known to be very painful and uncomfortable. Crohn's disease causes inflammation in the digestive tract and spreads along the tissue. The effects of this disease are severe diarrhea, malnutrition, and abdominal pain. Ulcerative colitis is another inflammatory bowel disease that is long-lasting. The symptoms of this disease develop over time, but it only affects the lining of the large intestine.

Doctors have not pinpointed the specific cause of IBD, but they are sure that stress and a poor diet are not the main factors. Researchers are now focusing on hereditary and the immune system as leading causes. If one or both of your parents has IBD, then chances of you having it are greater than if they didnâ??t. Researchers suggest that genetics may play a role in developing the disease. The immune system is another target for triggering IBD. Researchers believe that bacterium, or a virus, also prompts inflammatory bowel disease.

Symptoms of IBD come and go, and they may vary between each patient. Symptoms may include:

â?¢ Fever

â?¢ Loss of appetite

â?¢ Weight los

â?¢ Diarrhea

â?¢ Blood in stool

â?¢ Urgency to have a bowel movement

â?¢ Abdominal cramps

â?¢ Iron deficiency

Vedolizumab is being tested to treat the symptoms of inflammatory bowel disease. This treatmentâ??s purpose is to put the disease in remission so the patient will be able to live a healthy and normal life outside of the bathroom. Though the drug is not FDA approved yet, it has been tested on patients with Crohn's disease and ulcerative colitis. Common side effects of treatments for the disease are weight gain, headaches and nausea. However, Vedolizumab has not shown any listed side effects.